Citigroup
NMTC icon

Citigroup’s NeuroOne Medical Technologies NMTC Stock Holding History

Citigroup’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$757 Buy
+163
New +$783 ﹤0.01% 5502

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Citigroup's NMTC Position: Q1 2026 in Review

Citigroup opened a new position in NeuroOne Medical Technologies (NMTC) in Q1 2026: 163 shares worth $757. The stake represents ﹤0.01% of the portfolio and ranks #5502 among its holdings.

32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Citigroup held 163 shares of NeuroOne Medical Technologies worth $757 as of Q1 2026.
  • NeuroOne Medical Technologies was a new Citigroup position in Q1 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5502 holding.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.